C6 Ceramide

C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects[1][2][3][4][5].

Product Specifications

CAS Number

[124753-97-5]

Product Name Alternative

C6-Cer; N-Hexanoylsphingosine

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/c6-ceramide.html

Purity

99.82

Solubility

DMSO : ≥ 100 mg/mL

Smiles

CCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O

Molecular Formula

C24H47NO3

Molecular Weight

397.63

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhu Q, et, al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011 Jan 27;2 (1) :e117. |[2]Liu L, et, al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020 Aug 3;18 (1) :298. |[3]Mitoma J, et al. Bipotential roles of ceramide in the growth of hippocampal neurons: promotion of cell survival and dendritic outgrowth in dose- and developmental stage-dependent manners. J Neurosci Res. 1998 Mar 15;51 (6) :712-22.|[4]Flowers M, et al. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Res Treat. 2012 Jun;133 (2) :447-58. |[5]Wilhelm R, et al. C6 Ceramide (d18:1/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma. Cancers (Basel) . 2021 Jan 13;13 (2) :270.